Many epigenetic factors contribute to patients’ suffering from the consequences of chronic inflammation, excessive oxidative stress, immune system dysregulation, chronic infections, and mitochondrial dysfunction.  In many cases the root cause of the broad array of symptoms associated with such persistent conditions is not readily identified, and “shot in the dark” clinical interventions often do not result in patient satisfaction and improved quality of life.

Glutathione (GSH) is the quintessential tripeptide that has key modulatory roles in all of the aforementioned conditions. Insufficiency of GSH has been well established to be associated with the conditions, as has excessive environmental exposures to lead and household mold overgrowth.   Re-establishment of adequate GSH biosynthesis can be a challenge, especially when genetic issues limit the activity of enzymes involved in the biosynthesis and metabolism of GSH.  Appropriate laboratory testing can facilitate identification of the often elusive root causes of the chronic conditions, and guide well-targeted intravenous clinical intervention towards restoration of GSH homeostasis, biochemical and physiological function, and wellness.

This two-day event is designed to explore some of the clinically relevant evolving events in IV therapy using Alpha-Lipoic acid, EDTA, Glutathione, Vitamin C, and intervention for Mold and Mycotoxins, and Lyme Disease. The presenters are well known for their many years of work in research, analysis, and clinical practice. They will present substantive evidence of evolving trends and how they impact on clinical decisions, describing where evidence is preliminary, novel, or of greater substantiation. The conference will have a strong clinical bias and provide a welcome opportunity for questions and answers.


Upon completion of this activity, participants will be able to…

  1. Explain when and how to appropriately and safely administer the two distinctly different forms of EDTA for the purpose of lead detoxification (lead poisoning), and estimation of lead exposure using the lead mobilization test.
  2. Define the physiological roles of glutathione, and use GSH intravenously in cases of excessive exposure to environmental/occupational toxicants.
  3. Recall the roles and safe use of intravenously administered alpha-lipoic acid and glutathione in patients presenting with specific diseases and persistent illnesses.
  4. Describe and select the different applications of intravenous vitamin C as an anti-oxidant and pro-oxidant for patients with cancer verses hepatitis C.
  5. Justify and apply appropriate laboratory testing for a variety of persistent health conditions, and recall appropriate interpretation of results towards planning patient-specific intervention protocols.
  6. Discuss Chronic Inflammatory Response Syndrome, identify patients who are suspect for clinically significant exposure to mold, and apply appropriate testing for both the home and the patient.
  7. Explain the pathophysiological implications regarding Lyme disease and the position statement of the International Lyme and Associated Disease Society.
  8. Recognize when to consider chronic infections in differential diagnosis, and perform appropriate testing for Lyme and co-infections.


Saturday, January 20, 2018

Time Session Speaker Abstract
8:30 - 9:00 Registration
9:00 - 9:15 Welcome / Introduction Patrick
9:15 - 10:30 Chelation Therapy with EDTA/Indications for the Use of IV Glutathione Patrick View
10:30 - 11:00 Break
11:00 - 12:15 Clinical Implications for Intravenous Vitamin C Bauerschmidt View
12:15 - 1:30 Lunch (provided)
1:30 - 2:45 Rational for Appropriate Laboratory Testing Quig View
2:45 - 3:15 Break
3:15 - 4:30 Intravenous Glutathione and Alpha-Lipoic Acid Bauerschmidt View
4:30 - 5:15 Lyme Disease: Clinical Implications and Intervention McCann View

Sunday, January 21, 2018

Time Session Speaker Abstract
9:00 - 10:15 Lyme Disease: Clinical Implications and Intervention (cont’d) / Mold and Mycotoxins McCann View
10:15 - 10:45 Break
10:45 - 11:30 Mold and Mycotoxins: Clinical Intervention McCann View
11:30 - 12:00 Panel discussion / Q&A Panel

Recent Comments



    • No categories